We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    pamrevlumab | dmd

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04632940
Recruitment Status : Active, not recruiting
First Posted : November 17, 2020
Last Update Posted : January 27, 2023
Sponsor:
Information provided by (Responsible Party):
FibroGen

Brief Summary:
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every 2 weeks in ambulatory participants with Duchenne muscular dystrophy (DMD) (age 6 to <12 years).

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: Pamrevlumab Drug: Placebo Drug: Corticosteroids Phase 3

Detailed Description:

This is a global, randomized, double-blind, trial of pamrevlumab or placebo in combination with systemic corticosteroids in participants with DMD, aged 6 to <12 years (ambulatory participants only). Approximately 70 participants will be randomized at a 1:1 ratio to Arm A (pamrevlumab + systemic deflazacort or equivalent potency of corticosteroids administered orally) or Arm B (placebo+ systemic deflazacort or equivalent potency of corticosteroids administered orally), respectively. Randomization will be stratified by exon 44 deletion for analysis. Stratification has no impact upon treatment assignment nor dosage.

Participants must be fully informed of the potential benefits of approved products and make an informed decision when participating in a clinical trial in which they could be randomized to placebo.

The main study has 3 study periods:

  • Screening period: Up to 4 weeks
  • Treatment period: 52 weeks
  • Safety Follow-up period/final assessment: A visit 28 days (+/- 3 Days) and a final safety follow-up phone call 60 days (+ 3 Days) after the last dose

Each participant will receive pamrevlumab or placebo at 35 mg/kg every 2 weeks for up to 52 weeks. Participants who complete 52 weeks of treatment may be eligible for an open-label extension (OLE), offering extended treatment with pamrevlumab.

Participants who discontinue study treatment for any reason should be encouraged to return to the investigative site to complete final safety and efficacy assessments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Actual Study Start Date : December 11, 2020
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : May 31, 2024


Arm Intervention/treatment
Experimental: Pamrevlumab
Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
Drug: Pamrevlumab
Pamrevlumab will be administered per dose and schedule specified in the arm description.
Other Name: FG-3019

Drug: Corticosteroids
Systemic deflazacort or equivalent potency of corticosteroids administered orally

Placebo Comparator: Placebo
Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
Drug: Placebo
Placebo will be administered per schedule specified in the arm description.

Drug: Corticosteroids
Systemic deflazacort or equivalent potency of corticosteroids administered orally




Primary Outcome Measures :
  1. Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 [ Time Frame: Baseline, Week 52 ]

Secondary Outcome Measures :
  1. Change From Baseline in 4-Stair Climb Velocity (4SCV) Assessment at Week 52 [ Time Frame: Baseline, Week 52 ]
  2. Change From Baseline in the 10-Meter Walk/Run Test at Week 52 [ Time Frame: Baseline, Week 52 ]
  3. Change From Baseline in Time to Stand (TTSTAND) at Week 52 [ Time Frame: Baseline, Week 52 ]
  4. Change From Baseline in Time to Loss of Ambulation (LoA) at Week 52 [ Time Frame: Baseline, Week 52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 11 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Age, and consent:

  1. Males at least 6 to <12 years of age at screening initiation
  2. Written consent by participant and/or legal guardian as per regional/ country and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements

    DMD diagnosis:

  3. Medical history includes diagnosis of DMD and confirmed Duchenne mutation, including status of exon 44 using a validated genetic test.

    Pulmonary criteria:

  4. Average (of screening and Day 0) percent predicted forced vital capacity (FVC) above 45%
  5. On a stable dose of systemic corticosteroids for a minimum of 6 months, with no substantial change in dosage for a minimum of 3 months (except for adjustments for changes in body weight) prior to screening. Corticosteroid dosage should be in compliance with the DMD Care Considerations Working Group recommendations (for example, prednisone or prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day) or stable dose. A reasonable expectation is that dosage and dosing regimen would not change significantly for the duration of the study.

    Performance criteria:

  6. Able to complete 6-minute walking distance (6MWD) test with a distance of at least 270 meters but no more than 450 meters on two occasions within 3 months prior to randomization with ≤10% variation between these two tests.
  7. Able to rise (TTSTAND) from floor in <10 seconds (without aids/orthoses) at screening visit.
  8. Able to undergo magnetic resonance imaging (MRI) test for the lower extremities vastus lateralis muscle.

    Vaccination:

  9. Agreement to receive annual influenza vaccinations during the conduct of the study.

    Laboratory criteria:

  10. Adequate renal function: cystatin C ≤1.4 mg/liter (L)
  11. Adequate hematology and electrolytes parameters:

    1. Platelets >100,000/microliter (μL)
    2. Hemoglobin >12 grams (g)/deciliter (dL)
    3. Absolute neutrophil count >1500/μL
    4. Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P) levels are within a clinically accepted range for DMD participants
  12. Adequate hepatic function:

    1. No history or evidence of liver disease
    2. Gamma glutamyl transferase (GGT) ≤3x upper limit of normal (ULN)
    3. Total bilirubin ≤1.5xULN

Exclusion Criteria:

General Criteria:

  1. Concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function
  2. Severe intellectual impairment (for example, severe autism, severe cognitive impairment, severe behavioral disturbances) preventing the ability to perform study assessments in the Investigator's judgment
  3. Previous exposure to pamrevlumab
  4. Body mass index (BMI) ≥40 kg/square meter (m^2) or weight >117 kg
  5. History of

    1. allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
    2. hypersensitivity to study drug or any component of study drug
  6. Exposure to any investigational drug (for DMD or not), in the 30 days prior to screening initiation or use of approved DMD therapies (for example, eteplirsen, ataluren, golodirsen, casimersen) within 5 half-lives of screening, whichever is longer with the exception of the systemic corticosteroids, including deflazacort

    Pulmonary and Cardiac criteria:

  7. Requires ≥16 hours continuous ventilation
  8. Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the investigator might impact respiratory function
  9. Hospitalization due to respiratory failure within the 8 weeks prior to screening
  10. Severe uncontrolled heart failure (New York Heart Association [NYHA] Classes III-IV) or renal dysfunction, including any of the following:

    1. Need for intravenous diuretics or inotropic support within 8 weeks prior to screening
    2. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks prior to screening
    3. Participants with glomerular filtration rate (GFR) of less than 30 mL/minute (min)/1.73 m^2 or with other evidence of acute kidney injury as determined by investigator
  11. Arrhythmia requiring anti-arrhythmic therapy
  12. Any other evidence of clinically significant structural or functional heart abnormality

    Clinical judgment:

  13. The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, or any other relevant medical, surgical or psychiatric conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04632940


Locations
Show Show 52 study locations
Sponsors and Collaborators
FibroGen
Layout table for additonal information
Responsible Party: FibroGen
ClinicalTrials.gov Identifier: NCT04632940    
Other Study ID Numbers: FGCL-3019-094
2020-000699-39 ( EudraCT Number )
First Posted: November 17, 2020    Key Record Dates
Last Update Posted: January 27, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by FibroGen:
Duchenne Muscular Dystrophy, DMD
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked